Abstract 1800: Mitochondrial dysfunction induces asparaginase resistance in R-spondin fusion colorectal cancer

Abstract Improved therapies are required for the thousands of patients who die of colorectal cancer (CRC) every year. We previously found that asparaginase, a cancer therapeutic that degrades asparagine, has efficacy in R-spondin fusion CRCs because these fusions block upregulation of proteasomal protein degradation, a source of intracellular amino acids, when asparagine is lacking from the environment (Hinze et al., Cancer Discovery, 2020). To anticipate mechanisms of treatment resistance that may emerge, we applied a CRISPR-based genetic screen to identify modifiers of asparaginase response in R-spondin fusion CRC. We found that guide RNAs targeting multiple mitochondria-localized proteins were enriched in asparaginase-treated cells, as these genes comprised 59% of the top 100 “hits” on the screen. This finding suggested that impairing mitochondrial function induces asparaginase resistance, which was surprising because mitochondrial function is required to produce intracellular aspartate, a key substrate for asparagine biosynthesis. Indeed, in R-spondin fusion CRC driven cells, we confirmed that shRNA knockdown of multiple mitochondrial factors, or a pharmacologic inhibitor of mitochondrial translation, each induced asparaginase resistance. Mitochondria contain >1100 proteins, 99% of which are nuclear-encoded, cytoplasmically-synthesized, and then imported into mitochondria. We found that induction of mitochondrial dysfunction led to a marked increase in total K48-linked polyubiquitinated proteins, along with cytoplasmic accumulation of multiple nuclear-encoded mitochondria proteins. Our findings support the model that triggering mitochondrial dysfunction impairs mitochondrial import of nuclear-encoded mitochondrial proteins, which are then degraded via the ubiquitin proteasome system. This provides an alternative mechanism through which these cells can increase protein degradation despite expression of the R-spondin fusion. Protein degradation releases free amino acids, providing these cells with a catabolic source of intracellular asparagine that allows them to survive during asparaginase-induced depletion of asparagine. Our findings provide a molecular understanding of how the failure of import of mitochondrial proteins may be an anticipated mechanism of resistance to asparaginase in patients. Citation Format: Su Hyun Lee, Yun-Cheol Chae, Alejandro Gutierrez. Mitochondrial dysfunction induces asparaginase resistance in R-spondin fusion colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1800.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-1800
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 1800: Mitochondrial dysfunction induces asparaginase resistance in R-spondin fusion colorectal cancer

Yun‐Cheol Chae, Su Hyun Lee, Alejandro Gutierrez
Cancer Research
Cancer Research and Treatments
article

Abstract 1800: Mitochondrial dysfunction induces asparaginase resistance in R-spondin fusion colorectal cancer

Yun‐Cheol Chae, Su Hyun Lee, Alejandro Gutierrez
article en

Abstract

Abstract Improved therapies are required for the thousands of patients who die of colorectal cancer (CRC) every year. We previously found that asparaginase, a cancer therapeutic that degrades asparagine, has efficacy in R-spondin fusion CRCs because these fusions block upregulation of proteasomal protein degradation, a source of intracellular amino acids, when asparagine is lacking from the environment (Hinze et al., Cancer Discovery, 2020). To anticipate mechanisms of treatment resistance that may emerge, we applied a CRISPR-based genetic screen to identify modifiers of asparaginase response in R-spondin fusion CRC. We found that guide RNAs targeting multiple mitochondria-localized proteins were enriched in asparaginase-treated cells, as these genes comprised 59% of the top 100 “hits” on the screen. This finding suggested that impairing mitochondrial function induces asparaginase resistance, which was surprising because mitochondrial function is required to produce intracellular aspartate, a key substrate for asparagine biosynthesis. Indeed, in R-spondin fusion CRC driven cells, we confirmed that shRNA knockdown of multiple mitochondrial factors, or a pharmacologic inhibitor of mitochondrial translation, each induced asparaginase resistance. Mitochondria contain >1100 proteins, 99% of which are nuclear-encoded, cytoplasmically-synthesized, and then imported into mitochondria. We found that induction of mitochondrial dysfunction led to a marked increase in total K48-linked polyubiquitinated proteins, along with cytoplasmic accumulation of multiple nuclear-encoded mitochondria proteins. Our findings support the model that triggering mitochondrial dysfunction impairs mitochondrial import of nuclear-encoded mitochondrial proteins, which are then degraded via the ubiquitin proteasome system. This provides an alternative mechanism through which these cells can increase protein degradation despite expression of the R-spondin fusion. Protein degradation releases free amino acids, providing these cells with a catabolic source of intracellular asparagine that allows them to survive during asparaginase-induced depletion of asparagine. Our findings provide a molecular understanding of how the failure of import of mitochondrial proteins may be an anticipated mechanism of resistance to asparaginase in patients. Citation Format: Su Hyun Lee, Yun-Cheol Chae, Alejandro Gutierrez. Mitochondrial dysfunction induces asparaginase resistance in R-spondin fusion colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1800.

Cancer ResearchVol. 86(7_Supplement)
St. Jude Children's Research Hospital (US)
Good health and well-being
Openalex Percentile: Top 8%
Cancer Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.